Look at it this way. Novavax will be a whole new company by the end of the year. They have already shed all of their long term debt ($15 Million). Now they are going to start generating vaccine revenues from India, and perhaps other places. These two developments alone value NVAX much higher than past trading levels. Things could get much better if U.S. approval comes or other deals emerge.
News 
Market Data 
Discover 
AI
